Aeterna Zentaris (NASDAQ:AEZS) Now Covered by Analysts at StockNews.com

Posted by on Jun 23rd, 2023

StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a research report issued to clients and investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Aeterna Zentaris in a report on Tuesday, March 28th.

Aeterna Zentaris Stock Performance

NASDAQ:AEZS opened at $2.65 on Friday. The stock’s fifty day moving average price is $2.93 and its two-hundred day moving average price is $3.15. Aeterna Zentaris has a 52-week low of $2.32 and a 52-week high of $8.63. The company has a market cap of $12.87 million, a price-to-earnings ratio of -0.53 and a beta of 1.35.

Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.19. The business had revenue of $2.13 million for the quarter, compared to analyst estimates of $0.90 million. On average, equities analysts predict that Aeterna Zentaris will post -3.41 EPS for the current fiscal year.

About Aeterna Zentaris

(Get Rating)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

Recommended Stories

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.